Drug intelligence / Profile preview

VS-411

Development stage: Unknown
Lead developer: Virostatics
Modality: Small Molecules

Overview

VS-411 is a novel 4,6-disubstituted aminopyrimidine derivative that functions as a kinase inhibitor, specifically targeting host-cell kinases such as Cyclin-dependent kinase 9 (CDK9). Developed through a strategic partnership between ViroStatics and Vichem Chemie, this small molecule is being investigated for the treatment of HIV/AIDS and other chronic diseases. It represents an AntiViral-HyperActivation Limiting Therapeutic (AV-HALT) designed to modulate host-cell processes.

Targets

CDK9 (Cyclin-dependent kinase 9)

Beyond the preview

Go deeper on VS-411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-411.

Explore the full profile